Dupilumab for children with asthma in China
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been using a combination inhaler (ICS-LABA) for at least 3 to 6 months but their asthma is still not well-controlled.
- Your child has signs of 'type 2' asthma, such as high levels of a substance called FeNO (20 or more), a certain type of white blood cell (eosinophils) in sputum (2% or more), or in blood (300 or more).
- Your child is prescribed Dupilumab by their doctor during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
This trial tests whether dupilumab can help people with moderate-to-severe asthma achieve clinical remission. It may be an option if you have asthma with high levels of certain inflammatory markers and have had at least one asthma attack in the last 2 years.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
Hear when a new Asthma in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.